Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01243892 · ClinicalTrials.gov registry record
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
A clinical trial, sponsored by Genentech.
- Terminated
- Registry status
- 18
- Enrollment target
NCT01243892 is a clinical trial that was terminated before completion, run by Genentech. The registered enrollment target is 18 participants.
The verdict
NCT01243892 was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- 18 participants
- Enrollment target
Study Summary
This is a Phase IV, open label, case-controlled, observational study to evaluate the age-adjusted cumulative height velocity in pre-pubertal isolated growth hormone deficient (IGHD) and idiopathic short stature (ISS) participants receiving daily doses of somatropin (recombinant human growth hormone \[rhGH\]; Nutropin) using NuSpin device compared to historical controls from the national cooperative growth study (NCGS).
Interventions
- DRUG Somatropin
- DEVICE NuSpin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01243892
The ClinicalTrials.gov registry entry for NCT01243892 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Somatropin is the first listed.
NCT01243892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01243892 about?
NCT01243892 is a clinical study titled "A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device". This is a Phase IV, open label, case-controlled, observational study to evaluate the age-adjusted cumulative height velocity in pre-pubertal isolated growth hormone deficient (IGHD) and idiopathic short stature (ISS) participants receiving daily doses of somatropin (recombinant human growth hormone ...
What is the current status of trial NCT01243892?
This trial is currently terminated. The enrollment target is 18 participants. The study started on 2010-11. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01243892?
The interventions under investigation include: Somatropin (DRUG), NuSpin (DEVICE).
Who is sponsoring clinical trial NCT01243892?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.